Results 151 to 160 of about 27,184 (256)

Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir. [PDF]

Sci Rep
Kim H, Kim JY, Yoo HJ, Kim LY, Yoo JJ, Kim SG, Kim YS.   +6 more
europepmc   +1 more source

Patient Characteristics and Reasons for Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Retrospective Cohort From a Large Urban HIV Clinic. [PDF]

Cureus
Gao H, Manchukonda B, Simoes P, Hamlyn E, Barber TJ, Hunter A, Hart J, Johnson M, Kinloch-de Loes S.   +8 more
europepmc   +1 more source

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial. [PDF]

Hepatol Commun
Tabataba Vakili S, Hirode G, Zahoor A, Saunthar A, Feld JB, Hansen BE, Syeda A, Janssen HLA, Kukreti V, Kuruvilla J, Prica A, Cheung M, Buckstein R, Hicks L, Coffin CS, Street LE, Disperati P, Chan KK, Crump M, Feld JJ.   +19 more
europepmc   +1 more source

Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies. [PDF]

Infect Dis Ther
Antinori A, Yokomaku Y, Elinav H, Pullukçu H, de Wet J, Antela A, Lu PL, Sabranski M, Kim YS, Bonnet F, den Hollander J, Jackson A, Choy CY, Cai W, Zhang F, Thorpe D, Marongiu A, Harrison R, Jarrett J, Boffito M.   +19 more
europepmc   +1 more source

Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real-world evidence from the OPERA cohort. [PDF]

HIV Med
Pierone G, Brunet L, Fusco JS, Sension MG, Dunbar MS, Gruber J, Dieterich DT, Fusco GP.   +7 more
europepmc   +1 more source

Optimized strategy of switching to tenofovir alafenamide fumarate treatment for nucleos(t)ide analogue experienced patients with chronic hepatitis B. [PDF]

Front Med (Lausanne)
Hu X, Kong Y, Liu Y, Liu T, Ma A, Li Y, Zhang Y, Li J, Zhang L, Li G.   +9 more
europepmc   +1 more source

Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure-Editorial on "Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B". [PDF]

Korean J Gastroenterol
Lee SK.
europepmc   +1 more source

BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV-Infected Patients. [PDF]

AIDS Res Treat
Pérez-Calvo F, Jover-Diaz F, Delgado-Sánchez E, Peris-García J, Bernabéu-Martínez MÁ.   +4 more
europepmc   +1 more source

Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum. [PDF]

Clin Pharmacokinet
Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson P, Myer L, Celum C, Heffron R, Coleman J, Davey DJ, Hendrix CW, Momper JD, Bies R, Scott RK.   +15 more
europepmc   +1 more source

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR. [PDF]

Infect Chemother
Kim YS, Choi JY, Park DW, Kim SW, Kim TH, Ryu J, Harrison R, Lee JA, Park F, Lee SH.   +9 more
europepmc   +1 more source